Axitinib/axitinib targeted drug market price and medication guide in 2025

Axitinib/Axitinib is a highly efficient and selective second-generation targeted drug that mainly targets vascular endothelial growth factor receptors (VEGFR), including VEGFR-1, VEGFR-2 and VEGFR-3. These receptors play an important role in tumor angiogenesis and growth, so axitinib can effectively slow down tumor development by inhibiting the activity of these receptors. The drug has been approved in China and several countries for the treatment of patients with advanced renal cell carcinoma who have progressed after one systemic therapy.

According to recommendations, the starting dose of axitinib is 5mg daily divided into two doses. Patients can choose whether to take it with food, which provides patients with flexibility. During clinical treatment, doctors will adjust the dosage according to the patient's tolerance and efficacy, up to a maximum of 10 mg twice a day, or reduce the dosage appropriately as needed. This flexible dose adjustment mechanism allows physicians to more accurately optimize each patient's treatment plan.

Pharmacokinetic studies show that the drug concentration of axitinib shows a good linear relationship in the dose range of 1-20mg. This means that at the recommended dosage, the absorption and elimination processes of the drug comply with linear kinetic characteristics, providing a solid foundation for its safety and effectiveness in clinical applications.

Currently, the original drug of axitinib has been launched in China and has been included in the reimbursement scope of Class B medical insurance. Common packaging specifications include1mg 14 tablets and 5mg 28 tablets, etc. The price of each box is about more than 200 yuan. In overseas markets, the price of original research drugs may be as high as 600 yuan. In addition, there are also generic drugs of axitinib available on the market, whose ingredients are almost the same as the original drug. They mainly include products from Laos, India and Bangladesh, and are sold for about 100 yuan (the specific price may change due to exchange rate fluctuations).

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta